Results 241 to 250 of about 212,093 (280)

Mobile phone data analyses for public health research: a scoping review. [PDF]

Front Public Health
Cheng X, Jiang W, Liu S, Lou X, Li Y, Liu L, Li M, Wang X, Cen Y, Chong A, Chen Z.   +10 more
europepmc   +1 more source

R&D investment and total factor productivity in China's pharmaceutical industry: The moderating effect of the centralized procurement policy. [PDF]

PLoS One
Li X, Xu J.
europepmc   +1 more source

A cost-benefit analysis of adult immunization programs across ten countries: Modeling the socioeconomic value of immunization for older populations compared to no vaccination. [PDF]

Hum Vaccin Immunother
Chowdhury S, Brassel S, El Banhawi H, Bell E, Neri M, Steuten L.   +5 more
europepmc   +1 more source

From Efficacy to Scale: Addressing Digital Health's Original Sin.

J Med Internet Res
van Mierlo T.
europepmc   +1 more source

The Pharmaceutical Innovativeness Index: Supporting Value-Based Economic Regulation of Innovative Medicines. [PDF]

J Mark Access Health Policy
Gargano LP, Borin MC, Prata WM, Alvares-Teodoro J, Acurcio FA, Iunes RF, Guerra AA.   +6 more
europepmc   +1 more source

An ideological playground? Changes in community pharmacy ownership - a case study from four Nordic and Baltic countries. [PDF]

J Pharm Policy Pract
Hämeen-Anttila K, Almarsdóttir AB, Volmer D, Björnsdottir I, Kälvemark Sporrong S.   +4 more
europepmc   +1 more source

A pharmaceutical economic stimulus plan.

Minnesota medicine, 2009
openaire   +1 more source

Policies to promote affordability and access across the life cycle of costly new drugs.

BMJ
Kruja K, Mestre-Ferrandiz J, Hopkins MM, Ryll B, Kalo Z, Moon S.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Economic Evaluation of Pharmaceuticals

PharmacoEconomics, 1992
The increased pressures on health care budgets have emphasised the need to demonstrate the value for money from health technologies. Most major pharmaceutical companies have therefore commissioned cost-benefit or cost-effectiveness analysis of their products. There is an assumed analogy between clinical trains, which are required for product licensing,
openaire   +4 more sources